Austar Lifesciences Ltd. has announced that it expects to report a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025. This represents a significant increase compared to the approximately RMB16 million profit recorded for the previous year. The substantial profit growth is primarily attributed to a decrease in operating expenses due to a focus on strategic efficiency and a sustainable model for long-term value creation. The company is in the process of finalising its annual results, which are expected to be announced in late March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Austar Lifesciences Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12017652), on February 06, 2026, and is solely responsible for the information contained therein.